Abstract:
Disclosed is a biomarker of which gene expression levels are specifically increased or reduced for sensitive skin. The biomarker specific to sensitive skin is used in such a diagnostic kit for sensitive skin and a screening method of an abirritant. The biomarker for diagnosis of sensitive skin according to the present invention contains one or more gene selected from a group consisting of HLA-C, TCEA1, IGHA1, TFRC, S100A8, LOC652128, SERPINB13, EHF, FLJ10781, TP63, CDH1, TNFRSF19, GM2A, FKBP5, PI3, PSPH, HORMAD1, SPRR2G, and ACTR2 or a group consiting of KBTBD10, TTN, ACTA1, MYBPC1, MB, MYOZ1, TPM1, CA3, CASQ1, ENO3, RBP4, GYG2, PPP1R1A, PYGM, G0S2, NEB, H19, LIPE, PLIN, H19, GPAM, FABP4, CIDEC, LPL, PCK1, ADIPOQ, PDE3B, ACVR1C, LPL, FABP4, DKFZP761N09121, TNMD, ATP6V1B1, C8orf22, and CRISP3.
Abstract:
PURPOSE: A composition containing cinnamic acid derivatives, triazine derivatives, and methoxy phenyl acrylate derivatives is provided to remarkably reduce chemical decomposition in case of irradiating with light. CONSTITUTION: A composition for sun screening contains cinnamic acid derivatives, triazine derivatives, and methoxy phenyl acrylate derivatives as an active ingredient. The triazine derivative includes bis-ethyl hexcyloxyphenyl methoxy phenyl triazine, tris(diisobutyl-aminobenzalmalonate)triazine, or combination thereof. The methoxyphenyl acrylate derivative is ethyl hexyl methoxy crylene. The composition further contains salicylic acid derivatives and benzalonate derivatives.
Abstract:
PURPOSE: A composition for promoting differentiation of human mesenchymal stem cells into adipocytes is provided to enhance skin volume. CONSTITUTION: An external use skin composition for enhancing skin elasticity contains 0.0001-30 wt% of extract of Castaneae Semen, Selaginella tamariscina, Aloe vera L., Mentha arvensis var. piperascens Makinv., Pinellia ternata (Thunb.) Breit., Triticum aestivum L., Saururus chinensis Baill., Polygala tenuifolia Willd., or Gleditsia sinensis Lam. as an active ingredient. The composition promotes differentiation of mesenchymal stem cells into adipocytes. The mesenchymal stem cells are derived from human. A pharmaceutical composition for promoting differentiation of adipocytes contains the extract as an active ingredient.
Abstract:
PURPOSE: A composition containing an oligonucleotide or mimic acting as an inhibitor of miRNA-526b is provided to control collagen generation and to prevent or treat aging. CONSTITUTION: A composition for controlling collagen contains 15-23 serial nucleotides of sequence number 1. The collagen is controlled by regulating the expression of matrix metalloproteinase 1(MMP1). The oligonucleotide reduces or suppresses the expression of MMP1 by hybridization with MMP1 mRNA. The composition is used for anti-aging.
Abstract:
PURPOSE: A composition containing medicinal herb extract for skin care or plasty is provided to promote differentiation of mesenchymal stem cells to adipocytes. CONSTITUTION: A composition for promoting adipocyte differentiation contains Linderae Radix extract as an active ingredient. The composition increases fat tissue and promotes differentiation of mesenchymal stem cells to adipocytes. The mesenchymal stem cells are derived from human bone marrow.
Abstract:
PURPOSE: A composition of external use skin formulation for anti-aging and moisturizing is provided to suppress MMP(matrix metalloprotease) increase. CONSTITUTION: A composition of external use skin formulation contains 0.001-10 weight% of 11,14,17-Eicosatrienoic acid(ETA) as an active ingredient. ETA is contained in oil phase. The composition is used for preventing aging through reduction of collagenase expression. The composition is also used for skin moisturizing by suppressing skin barrier damage.
Abstract:
PURPOSE: A method for screening a material which relieves skin irritation by environmental harmful factor is provided to manufacture an external use formulation and to detoxify. CONSTITUTION: A method for screening a material which relieves skin irritation by environmental harmful factor comprises: a step of treating candidates which regulates intracellular factor in vitro; a step of treating the environmental harmful factor to test cells to induce overexpression of the factor; and a step of measuring expression level. The test cells are keratinocytes. The environmental harmful factor is pollen or yellow sand. The overexpressed factor is interleukin 6 or 8, GSTT1, NQ01, or hBD3. The screened material is Melia azedarach L. var. japonica Makino or Tussilago farfara L. extract.
Abstract:
PURPOSE: A method for screening a material which induces skin irritation by yellow dust is provided to reduce skin irritative factor expression and to reduce skin irritation by yellow dust. CONSTITUTION: A method for screening a material which induces skin irritation by yellow dust comprises: a step of treating yellow dust to keratinocytes; and a step of screening a gene of which expression level is significantly changed comparing with the expression of normal keratinocytes through RT-PCR. The material which induces skin irritation by yellow dust is AhR or CYP. A method for screening a material which relieves skin irritation by yellow dust comprises: a step of treating yellow dust to test cells to induce overexpression of an irritative factor; a step of treating a candidate material to the overexpressed cells; a step of measuring expression level of the irritative factor by RT-PCR. The material which relieves skin irritation by yellow dust is Trichosanthis semen. An external use skin composition for relieving skin irritation contains 0.001-1 weight% of Trichosanthis semen.
Abstract:
PURPOSE: A method for screening dynamic stimulation for improving skin function is provided to measure biochemical change against external stimulation and screen kind, form, size, intensity, and time of dynamic stimulation. CONSTITUTION: A method for screening dynamic stimulation for improving skin function comprises: a first step of performing repeatitive dynamic stimulation to skin; a second step of measuring biochemical change of skin by dynamic stimulation; and a third step of selecting useful dynamic stimulation based on biochemical change. The measurement is performed by measuring mRNA expression level of fibroblast-derived gene. In the third step, nerve growth factor, neurotrophin 3, TIMP 1, TrkA, TrkC, TGF alpha, TGF beta1, TGF beta2 or TGF beta3 gene is selected as dynamic stimulation.